Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, talks on the impact of COVID-19 on myeloma research and outlines the latest updates from both preclinical and clinical studies. Prof. Raje explains that research has made significant advances in improving understanding of myeloma precursor diseases, the genetics underlying disease development and progression, as well as on the risk factors which can be used to better delineate myeloma subgroups. Prof. Raje also highlights novel therapeutic strategies which have been recently approved or are under development, such as degronomids. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Noopur Raje, MD, has participated in consulting for Amgen, BMS, GSK, Janssen, Takeda, Oncopeptides, Karyopharm, Bluebird Bio, Pfizer, AstraZeneca; has participated in the advisory boards of Immuneel and Caribou; and has received research funding from Bluebird Bio,